Reproducibility of QuantiFERON-TB Gold In-tube Assay

Overview

Journal Clin Vaccine Immunol

Publisher American Society for Microbiology

Specialties Allergy & Immunology
Pathology

Date 2008 Jan 18

PMID 18199741

Citations 36

Authors

Sharon Perry

Luz Sanchez

Shufang Yang

Zubin Agarwal

Philip Hurst

Julie Parsonnet

Affiliations

Soon will be listed here.

Abstract

Studies are needed to characterize the reproducibility of QuantiFERON-TB Gold (QFT-G) for targeted U.S. screening populations. Members of northern California households were tested with the QFT-G in-tube assay (QFT-G-IT) at two home visits 3 months apart. Reproducibility and agreement with the tuberculin skin test (TST) were assessed. Monte Carlo simulation was used to evaluate the role of test-related error. Of 63 individuals (49 adults and 14 children) completing QFT-G-IT at both time points, 79% were foreign-born (98% from Latin America) and 68% reported Mycobacterium bovis BCG vaccination. At the baseline visit, 23 (37%) were TST positive and 15 (24%) were QFT-G-IT positive (kappa = 0.48 [+/- 0.11]). At 3 months, 3/48 (6.3%; 95% confidence interval [95CI], 2 to 17) of those initially QFT-G-IT negative converted, and 5/15 (33%; 95CI, 15 to 58) of those initially QFT-G-IT positive reverted. Among the 8 individuals with inconsistent QFT-G-IT results, the maximum gamma interferon response at either visit was 0.68 IU/ml versus means of 4.99 (+/- 3.74) and 6.95 (+/- 5.6) for 10 persistent positives at the first and second visits, respectively. Expected false-reversion and -conversion rates were 32% (90CI, 25 to 39%) and 6.95% (90CI, 4.6 to 9.8%) when the sensitivity and specificity were assumed to average 70% and 98%, respectively. Transient responses to QFT-G-IT are common, and low positive results need to be interpreted with caution. Further studies are needed to characterize the predictive value of the test for U.S. foreign-born and other targeted screening populations.

Citing Articles

Enhancing the interferon-γ release assay through omission of nil and mitogen values.

Jung Y, Park J, Park J, Lee K, Chung W, Park J Respir Res. 2023; 24(1):179.

PMID: 37420251 PMC: 10327336. DOI: 10.1186/s12931-023-02485-4.

Tuberculosis Infection Screening in 5468 Italian Healthcare Students: Investigation of a Borderline Zone Value for the QFT-Test.

Corvino A, Monaco M, Garzillo E, Grimaldi E, Donnarumma G, Miraglia N Int J Environ Res Public Health. 2020; 17(18).

PMID: 32957500 PMC: 7557828. DOI: 10.3390/ijerph17186773.

infection among persons who inject drugs in San Diego, California.

Armenta R, Collins K, Strathdee S, Bulterys M, Munoz F, Cuevas-Mota J Int J Tuberc Lung Dis. 2017; 21(4):425-431.

PMID: 28284258 PMC: 6352726. DOI: 10.5588/ijtld.16.0434.

QFT-Plus: a plus in variability? - Evaluation of new generation IGRA in serial testing of students with a migration background in Germany.

Knierer J, Gallegos Morales E, Schablon A, Nienhaus A, Kersten J J Occup Med Toxicol. 2017; 12:1.

PMID: 28070206 PMC: 5216544. DOI: 10.1186/s12995-016-0148-z.

Antigen-Specific IFN- Responses Correlate with the Activity of Infection but Are Not Associated with the Severity of Tuberculosis Disease.

Nikitina I, Panteleev A, Sosunova E, Karpina N, Bagdasarian T, Burmistrova I J Immunol Res. 2017; 2016:7249369.

PMID: 28042583 PMC: 5155109. DOI: 10.1155/2016/7249369.

References

Pottumarthy S, Morris A, Harrison A, Wells V . Evaluation of the tuberculin gamma interferon assay: potential to replace the Mantoux skin test. J Clin Microbiol. 1999; 37(10):3229-32. PMC: 85534. DOI: 10.1128/JCM.37.10.3229-3232.1999. View

Menzies D . Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med. 1999; 159(1):15-21. DOI: 10.1164/ajrccm.159.1.9801120. View

Kang Y, Lee H, Yoon H, Cho B, Han S, Shim Y . Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA. 2005; 293(22):2756-61. DOI: 10.1001/jama.293.22.2756. View

Nguyen M, Perry S, Parsonnet J . QuantiFERON-TB predicts tuberculin skin test boosting in U.S. foreign-born. Int J Tuberc Lung Dis. 2005; 9(9):985-91. View

Perry S, Parsonnet J . Commentary: H. pylori infection in early life and the problem of imperfect tests. Int J Epidemiol. 2005; 34(6):1356-8. DOI: 10.1093/ije/dyi243. View

Mazurek G, Jereb J, LoBue P, Iademarco M, Metchock B, Vernon A . Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep. 2005; 54(RR-15):49-55. View

Porsa E, Cheng L, Seale M, Delclos G, Ma X, Reich R . Comparison of a new ESAT-6/CFP-10 peptide-based gamma interferon assay and a tuberculin skin test for tuberculosis screening in a moderate-risk population. Clin Vaccine Immunol. 2006; 13(1):53-8. PMC: 1356632. DOI: 10.1128/CVI.13.1.53-58.2006. View

Demissie A, Leyten E, Abebe M, Wassie L, Aseffa A, Abate G . Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. Clin Vaccine Immunol. 2006; 13(2):179-86. PMC: 1391929. DOI: 10.1128/CVI.13.2.179-186.2006. View

Jeffries D, Hill P, Fox A, Lugos M, Jackson-Sillah D, Adegbola R . Identifying ELISPOT and skin test cut-offs for diagnosis of Mycobacterium tuberculosis infection in The Gambia. Int J Tuberc Lung Dis. 2006; 10(2):192-8. View

10.

Mahomed H, Hughes E, Hawkridge T, Minnies D, Simon E, Little F . Comparison of mantoux skin test with three generations of a whole blood IFN-gamma assay for tuberculosis infection. Int J Tuberc Lung Dis. 2006; 10(3):310-6. View

11.

Dewan P, Grinsdale J, Liska S, Wong E, Fallstad R, Kawamura L . Feasibility, acceptability, and cost of tuberculosis testing by whole-blood interferon-gamma assay. BMC Infect Dis. 2006; 6:47. PMC: 1434750. DOI: 10.1186/1471-2334-6-47. View

12.

Ferrara G, Losi M, DAmico R, Roversi P, Piro R, Meacci M . Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet. 2006; 367(9519):1328-34. DOI: 10.1016/S0140-6736(06)68579-6. View

13.

Connell T, Curtis N, Ranganathan S, Buttery J . Performance of a whole blood interferon gamma assay for detecting latent infection with Mycobacterium tuberculosis in children. Thorax. 2006; 61(7):616-20. PMC: 2104654. DOI: 10.1136/thx.2005.048033. View

14.

Pai M, Joshi R, Dogra S, Mendiratta D, Narang P, Kalantri S . Serial testing of health care workers for tuberculosis using interferon-gamma assay. Am J Respir Crit Care Med. 2006; 174(3):349-55. PMC: 2648116. DOI: 10.1164/rccm.200604-472OC. View

15.

Brock I, Ruhwald M, Lundgren B, Westh H, Mathiesen L, Ravn P . Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-gamma test. Respir Res. 2006; 7:56. PMC: 1523341. DOI: 10.1186/1465-9921-7-56. View

16.

Pai M, Kalantri S, Menzies D . Discordance between tuberculin skin test and interferon-gamma assays. Int J Tuberc Lung Dis. 2006; 10(8):942-3. View

17.

Farhat M, Greenaway C, Pai M, Menzies D . False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria?. Int J Tuberc Lung Dis. 2006; 10(11):1192-204. View

18.

Dewan P, Grinsdale J, Kawamura L . Low sensitivity of a whole-blood interferon-gamma release assay for detection of active tuberculosis. Clin Infect Dis. 2006; 44(1):69-73. DOI: 10.1086/509928. View

19.

Hill P, Jeffries D, Brookes R, Fox A, Jackson-Sillah D, Lugos M . Using ELISPOT to expose false positive skin test conversion in tuberculosis contacts. PLoS One. 2007; 2(1):e183. PMC: 1779806. DOI: 10.1371/journal.pone.0000183. View

20.

Perry S, Sanchez M, Yang S, Haggerty T, Hurst P, Perez-Perez G . Gastroenteritis and transmission of Helicobacter pylori infection in households. Emerg Infect Dis. 2007; 12(11):1701-8. PMC: 3372328. DOI: 10.3201/eid1211.060086. View